Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We sought to confirm a bidirectional association between severe hypoglycemic events (SHEs) and cardiovascular (CV) event risk and to characterize individuals at dual risk. RESEARCH DESIGN AND METHODS: In a post hoc analysis of 14,752 Exenatide Study of Cardiovascular Event Lowering (EXSCEL) participants, we examined time-dependent associations between SHEs and subsequent major adverse cardiac events (CV death, nonfatal myocardial infarction [MI] or stroke), fatal/nonfatal MI, fatal/nonfatal stroke, hospitalization for acute coronary syndrome (hACS), hospitalization for heart failure (hHF), and all-cause mortality (ACM), as well as time-dependent associations between nonfatal CV events and subsequent SHEs. RESULTS: SHEs were uncommon and not associated with once-weekly exenatide therapy (hazard ratio 1.13 [95% CI 0.94–1.36], P = 0.179). In fully adjusted models, SHEs were associated with an increased risk of subsequent ACM (1.83 [1.38–2.42], P < 0.001), CV death (1.60 [1.11–2.30], P = 0.012), and hHF (2.09 [1.37–3.17], P = 0.001), while nonfatal MI (2.02 [1.35–3.01], P = 0.001), nonfatal stroke (2.30 [1.25–4.23], P = 0.007), hACS (2.00 [1.39–2.90], P < 0.001), and hHF (3.24 [1.98–5.30], P < 0.001) were all associated with a subsequent increased risk of SHEs. The elevated bidirectional time-dependent hazards linking SHEs and a composite of all CV events were approximately constant over time, with those individuals at dual risk showing higher comorbidity scores compared with those without. CONCLUSIONS: These findings, showing greater risk of SHEs after CV events as well as greater risk of CV events after SHEs, validate a bidirectional relationship between CV events and SHEs in patients with high comorbidity scores.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A causal relationship between hypoglycaemia and adverse outcomes is not always clear as low glucose levels can be a marker of ill health.139,140”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [140]
In the citing paper
“Similar results were confirmed in other trials.140,187,188”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [140]
In the citing paper
“Although severe hypoglycaemic events were associated with higher HF hospitalization in some but not all studies, there is no clear evidence for causality.139,140,554,568”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [140]
In the citing paper
“Recent analyses have demonstrated bi-directional associations between hypoglycaemia and CV outcomes, including HF, suggesting that this is not causal, but rather reflects underlying frailty and risk of adverse outcomes.139,140”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [140]
In the citing paper
“Although severe hypoglycaemic events were associated with higher HF hospitalization in some but not all studies, there is no clear evidence for causality.139,140,554,568”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [140]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742 · cited 7×
“diabetes (years) 12 (7, 17) 14 (9, 22) 16 (11, 22) 17 (10, 24) 12 (7, 18)”
MethodInfluentialGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 2×
“These findings, and the lack of compelling evidence for CV benefit from intensive glycemic control in patients with established CV disease, have prompted many diabetes management guidelines to suggest relaxing individual glycated hemoglobin (HbA1c) targets in such patients in the anticipation that this will reduce SHE…”
BackgroundSelf-citationAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 3×
“We sought to confirm in this post hoc analysis of data from EXSCEL (Exenatide Study of Cardiovascular Event Lowering) (16) that there is a bidirectional relationship between an increased risk for CV events after SHEs and an increased risk for SHEs after nonfatal CV events, particularly in patients at dual risk with fe…”
BackgroundResultSelf-citation(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933 · cited 5×
“Higher HbA1c targets, however, may increase the risk of microvascular complications in the longer term,andhavenotbeenshownto reduce the risk of SHEs (4,12,13).”
BackgroundResultSelf-citationWhy Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work
Austin, S. R., Wong, Y.-N., Uzzo, R. G., Beck, J. R., & Egleston, B. L. (2015) · Medical Care · doi:10.1097/mlr.0b013e318297429c · Cited by 716 · cited 7×
“diabetes (years) 12 (7, 17) 14 (9, 22) 16 (11, 22) 17 (10, 24) 12 (7, 18)”
MethodInfluentialZoungas, S., Arima, H., Gerstein, H. C., Holman, R. R., Woodward, M., Reaven, P., Hayward, R. A., Craven, T., Coleman, R. L., & Chalmers, J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30104-3 · Cited by 529
Self-citationAmiel, S. A., Aschner, P., Childs, B., Cryer, P. E., de Galan, B. E., Frier, B. M., Gonder-Frederick, L., Heller, S. R., Jones, T., Khunti, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30315-2 · Cited by 526
Hypoglycemia, Diabetes, and Cardiovascular Events
Desouza, C. V., Bolli, G. B., & Fonseca, V. (2010) · Diabetes Care · doi:10.2337/dc09-2082 · Cited by 443
Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1278 · Cited by 406
Self-citationAssociation of Hypoglycemia and Cardiac Ischemia
Desouza, C., Salazar, H., Cheong, B., Murgo, J., & Fonseca, V. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1485 · Cited by 406
Hypoglycemia and cardiovascular risks
Frier, B. M., Schernthaner, G., & Heller, S. R. (2011) · Diabetes Care · doi:10.2337/dc11-s220 · Cited by 381
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
The ORIGIN Trial Investigators, Mellbin, L. G., Rydén, L., Riddle, M. C., Probstfield, J., Rosenstock, J., Díaz, R., Yusuf, S., & Gerstein, H. C. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht332 · Cited by 247
Antecedent Hypoglycemia Impairs Autonomic Cardiovascular Function
Adler, G. K., Bonyhay, I., Failing, H., Waring, E., Dotson, S., & Freeman, R. (2009) · Diabetes · doi:10.2337/db08-1153 · Cited by 216
Stahn, A., Pistrosch, F., Ganz, X., Teige, M., Koehler, C., Bornstein, S., & Hanefeld, M. (2014) · Diabetes Care · doi:10.2337/dc13-0600 · Cited by 173
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
on behalf of the DEVOTE Study Group, Pieber, T. R., Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pratley, R. E., Woo, V. C., Heller, S. R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4422-0 · Cited by 160
Self-citationTsutamoto, T., Tanaka, T., Sakai, H., Ishikawa, C., Fujii, M., Yamamoto, T., & Horie, M. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm154 · Cited by 149 · cited 1×
“Heart failure patientswith the highest levels of both natriuretic peptides and adiponectin have been found to have the highest mortality risk (38).”
BackgroundDeath during intensive glycemic therapy of diabetes: mechanisms and implications
Cryer, P. E. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.008 · Cited by 137 · cited 1×
“HDL (mg/dL) 42 (35, 50) 42 (35, 49) 42 (34, 49) 38 (32, 44) 42 (35, 50)”
Davis, S. N., Duckworth, W. C., Emanuele, N., Hayward, R. A., Wiitala, W. L., Thottapurathu, L., Reda, D. J., & Reaven, P. D. (2018) · Diabetes Care · doi:10.2337/dc18-1144 · Cited by 136 · cited 1×
“increased risk of 60% for CV death and ;80% for all-cause death after an SHE is quite comparable with other publications including the finding of these hazards beingmost frequent close to an SHE (3,4,6,7,9,20,21).”
ResultLee, A. K., Rawlings, A. M., Lee, C. J., Gross, A. L., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2018) · Diabetologia · doi:10.1007/s00125-018-4668-1 · Cited by 115 · cited 2×
“diabetes (years) 12 (7, 17) 14 (9, 22) 16 (11, 22) 17 (10, 24) 12 (7, 18)”
BackgroundHypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
Zinman, B., Marso, S. P., Christiansen, E., Calanna, S., Rasmussen, S., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dc17-2677 · Cited by 113
Self-citationTsujimoto, T., Yamamoto-Honda, R., Kajio, H., Kishimoto, M., Noto, H., Hachiya, R., Kimura, A., Kakei, M., & Noda, M. (2014) · Diabetes Care · doi:10.2337/dc13-0701 · Cited by 103
Mellbin, L., Malmberg, K., Waldenström, A. P., Wedel, H., Rydén, L., & for the DIGAMI 2 investigators (2008) · Heart · doi:10.1136/hrt.2008.152835 · Cited by 88
Standl, E., Stevens, S. R., Armstrong, P. W., Buse, J. B., Chan, J. C. N., Green, J. B., Lachin, J. M., Scheen, A., Travert, F., Van de Werf, F., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1778 · Cited by 76 · cited 7×
“Of note, a strong reverse association, in which nonfatal CV events were associated with a subsequent increased risk of SHEs, was demonstrated in a post hoc analysis of TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) (8).”
BackgroundResultSelf-citationKong, A. P. S., Yang, X., Luk, A. O. Y., Ronald, C. W., So, W. Y., Ozaki, R., Ting, R. Z. W., Cheung, K. K.-T., Ho, C. S., Chan, M. H. M., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2507 · Cited by 75
Jordan, J., Birkenfeld, A. L., Melander, O., & Moro, C. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11081 · Cited by 68 · cited 2×
“In terms of SHEs occurring after a CV event including hHF, brain natriuretic peptides may play an important role, as theydamong many other effectsd activate insulin-sensitizing mechanisms at the level of skeletalmuscle and adipose tissue and increase circulating concentrations of the insulin-sensitizing hormone adipon…”
BackgroundHeart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Standl, E., Schnell, O., & McGuire, D. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.306924 · Cited by 65
Self-citationNatriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes
Coué, M., Barquissau, V., Morigny, P., Louche, K., Lefort, C., Mairal, A., Carpéné, C., Viguerie, N., Arner, P., Langin, D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19619-0 · Cited by 57 · cited 2×
“In terms of SHEs occurring after a CV event including hHF, brain natriuretic peptides may play an important role, as theydamong many other effectsd activate insulin-sensitizing mechanisms at the level of skeletalmuscle and adipose tissue and increase circulating concentrations of the insulin-sensitizing hormone adipon…”
BackgroundCardiovascular Implications of Hypoglycemia in Diabetes Mellitus
Connelly, K. A., Yan, A. T.-K., Leiter, L. A., Bhatt, D. L., & Verma, S. (2015) · Circulation · doi:10.1161/circulationaha.115.015946 · Cited by 54
Liberating A1C goals in older adults may not protect against the risk of hypoglycemia
Munshi, M. N., Slyne, C., Segal, A. R., Saul, N., Lyons, C., & Weinger, K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.014 · Cited by 52 · cited 1×
“Higher HbA1c targets, however, may increase the risk of microvascular complications in the longer term,andhavenotbeenshownto reduce the risk of SHEs (4,12,13).”
BackgroundZaccardi, F., Dhalwani, N. N., Webb, D. R., Davies, M. J., & Khunti, K. (2018) · Diabetologia · doi:10.1007/s00125-018-4626-y · Cited by 45
Mentz, R. J., Bethel, M. A., Merrill, P., Lokhnygina, Y. V., Buse, J. B., Chan, J. C. N., Felício, J. S., Goodman, S. G., Choi, J., Gustavson, S. M., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009304 · Cited by 36 · cited 1×
“Partially adjusted models included randomized treatment and clinical factors of age, sex, ethnicity, weight, and current smoking, while models fully adjusted for independent predictors of MACE and ACM in EXSCEL (19) included age, sex, ethnicity, HbA1c, New York Heart Association class, current smoking, randomized trea…”
MethodSelf-citationHypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry
Kong, A. P. S., Yang, X., Luk, A. O. Y., Cheung, K. K., Ronald, C. W., So, W. Y., Ho, C. S., Chan, M. H. M., Ozaki, R., Chow, C. C., et al. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-48 · Cited by 35
Jungmann, E., Konzok, C., H�ll, E., Fassbinder, W., & Sch�ffling, K. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637742 · Cited by 13 · cited 1×
“Anaugmentingeffect of atrial natriuretic peptide on insulininduced hypoglycemia has long been known (36).”
Background
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationThe Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationThe consequences of hypoglycaemia
Amiel, S. A. (2021) · Diabetologia · doi:10.1007/s00125-020-05366-3 · Cited by 223
The double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 55
“Although severe hypoglycemic events were associated with higher HF hospitalization [157–160], recent analyses have revealed a bi-directional association between hypoglycemia and CV outcomes, including HF.”
BackgroundMcAlister, F. A., Zheng, Y., Westerhout, C. M., Buse, J. B., Standl, E., McGuire, D. K., de Werf, F. V., Green, J. B., Armstrong, P. W., Holman, R. R., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1958 · Cited by 36
Self-citation
Metadata
- Authors
- Standl, E., Stevens, S. R., Lokhnygina, Y., Bethel, M. A., Buse, J. B., Gustavson, S. M., Maggioni, A. P., Mentz, R. J., Hernandez, A. F., & Holman, R. R.
- Affiliations
- Helmholtz Munich (DE)
- Duke University (US)
- University of Oxford (GB)
- University of North Carolina at Chapel Hill (US)
- AstraZeneca (United States) (US)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Corresponding author
- Standl, Eberhard
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-03-01
- Volume
- 43
- Issue
- 3
- Pages
- 643-652
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2997790100
- Cited by
- 65
- References
- 38
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 7 · 2022: 10 · 2021: 12 · 2020: 19
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Amgen
- Eli Lilly and Company
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Boston Scientific Corporation
- MannKind Corporation
- Fresenius Medical Care North America
- MyoKardia
- Zafgen
- National Institute for Health and Care Research (NF-SI-0515-10096)
- Novo Nordisk
- Servier
- National Institutes of Health (UL1TR002489)
- Genentech
- Duke Clinical Research Institute
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- cardiovascular events, type 2 diabetes, bidirectional relationship, exenatide, GLP-1 receptor agonists, major adverse cardiovascular events, heart failure hospitalization, myocardial infarction, stroke, all-cause mortality, comorbidities, EXSCEL trial
- MeSH terms
- Exenatide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Female, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Risk Factors, Severity of Illness Index, Comorbidity, Stroke, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.